"Veronica Francardo, PhD Lund University ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism"
And lastly I thought I remembered a May 24, 2018 upcoming conference abstract from Spain that the board found a few weeks back, also by Dr Veronica Francardo, the PD researcher affiliated with the MJF Foundation, in which the below copy/pasted excerpt was derived (but now I can't find a link to a May 2018 abstract):
"Using the same animal model of PD as in our previous study (i.e. intrastriatal 6-OHDA mouse model), we investigated the potential neurorestorative effects of ANAVEX 2-73, a compound with activity at both Sigma-1 and muscarinic receptors that is currently being tested in people affected by Alzheimer´s disease. Our results reveal that ANAVEX 2-73 is able to ameliorate parkinsonian motor symptoms in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts neuroprotective/neurorestorative effects on the nigrostriatal dopamine system."